Product Comparison


  AbbVie US LLC 00074107001 AbbVie Inc 00074210001 AbbVie Inc 00074105001 AbbVie US LLC 00074501501 AbbVie US LLC 0074106501
McKesson # 1212568 1194022 1194021 1212567 1221601
Description SKYRIZI® Risankizumab-rzaa 150 mg / mL Injection Single-Dose Prefilled Cartridge 2.4 mL SKYRIZI® Risankizumab-rzaa 150 mg / mL Injection Prefilled Auto-Injector 1 mL SKYRIZI® Risankizumab-rzaa 150 mg / mL Injection Prefilled Syringe 1 mL SKYRIZI® Risankizumab-rzaa 60 mg / mL Injection Single-Dose Vial 10 mL SKYRIZI® Risankizumab-rzaa 150 mg / mL Injection Single-Dose Prefilled Cartridge 1.2 mL
Manufacturer # 000741070010007421000100074105001000745015010074106501
Brand SKYRIZI®SKYRIZI®SKYRIZI®SKYRIZI®SKYRIZI®
Manufacturer AbbVie US LLCAbbVie IncAbbVie IncAbbVie US LLCAbbVie US LLC
Invoice SKYRIZI, INJ 360MG/2.4ML PF CARTRIDGE W/OBI D/SSKYRIZI, PEN 150MG/MLSKYRIZI, PFS 150MG/MLSKYRIZI, SDV 600MG/10ML D/SSKYRIZI, INJ 180MG/1.2ML PF CARTRIDGE W/OBI D/S
    Log In to Order   Log In to Order   Log In to Order   Log In to Order   Log In to Order

Comparison

Container Type Single-Dose Prefilled CartridgePrefilled Auto-InjectorPrefilled SyringeSingle-Dose VialSingle-Dose Prefilled Cartridge
Country of Origin GermanyGermanyGermanyUnited StatesGermany
Generic Drug Code 5247549591496175247353397
NDC Number 0007410700100074210001000741050010007450150100074106501
Strength 150 mg / mL150 mg / mL150 mg / mL60 mg / mL150 mg / mL
Type SubcutaneousSubcutaneousSubcutaneousIntravenousSubcutaneous
UNSPSC Code 4214261951241200512412004214261951241200
Volume 2.4 mL1 mL1 mL10 mL1.2 mL
Application Monoclonal AntibodyMonoclonal AntibodyMonoclonal AntibodyMonoclonal AntibodyMonoclonal Antibody
Dosage Form InjectionInjectionInjectionInjectionInjection
Generic Drug Name Risankizumab-rzaaRisankizumab-rzaaRisankizumab-rzaaRisankizumab-rzaaRisankizumab-rzaa
Product Dating McKesson Acceptable Dating: we will ship >= 180 daysMcKesson Acceptable Dating: we will ship >= 180 daysMcKesson Acceptable Dating: we will ship >= 180 daysMcKesson Acceptable Dating: we will ship >= 180 daysMcKesson Acceptable Dating: we will ship >= 180 days
Storage Requirements Requires RefrigerationRequires RefrigerationRequires RefrigerationRequires RefrigerationRequires Refrigeration
Features and Benefits
  • SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
  • SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults
  • SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults
  • 360 mg/2.4 mL (150 mg/mL) single-dose prefilled cartridge with on-body injector
  • Store in a refrigerator at 36°F to 46° F (2°C to 8°C)
  • SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
  • Single-Dose Pen
  • SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
  • Single-Dose Prefilled Syringe
  • SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
  • SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults
  • SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults
  • 600 mg/10 mL (60 mg/mL) single-dose vial
  • SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
  • 180 mg/1.2 mL (150 mg/mL) single-dose prefilled cartridge with on-body injector